153 related articles for article (PubMed ID: 29098809)
1. Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya.
Coetzer M; Ledingham L; Diero L; Kemboi E; Orido M; Kantor R
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29098809
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
Perrier M; Castain L; Regad L; Todesco E; Landman R; Visseaux B; Yazdanpanah Y; Rodriguez C; Joly V; Calvez V; Marcelin AG; Descamps D; Charpentier C
J Antimicrob Chemother; 2019 Jun; 74(6):1679-1692. PubMed ID: 30768160
[TBL] [Abstract][Full Text] [Related]
3. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
Castain L; Perrier M; Charpentier C; Palich R; Desire N; Wirden M; Descamps D; Sayon S; Landman R; Valantin MA; Joly V; Peytavin G; Yazdanpanah Y; Katlama C; Calvez V; Marcelin AG; Todesco E
J Antimicrob Chemother; 2019 Jul; 74(7):2019-2023. PubMed ID: 31050739
[TBL] [Abstract][Full Text] [Related]
4. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
Giandhari J; Basson AE; Sutherland K; Parry CM; Cane PA; Coovadia A; Kuhn L; Hunt G; Morris L
Antimicrob Agents Chemother; 2016 Apr; 60(4):2248-56. PubMed ID: 26833162
[TBL] [Abstract][Full Text] [Related]
5. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.
Giandhari J; Basson AE; Coovadia A; Kuhn L; Abrams EJ; Strehlau R; Morris L; Hunt GM
AIDS Res Hum Retroviruses; 2015 Aug; 31(8):776-82. PubMed ID: 25919760
[TBL] [Abstract][Full Text] [Related]
6. Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.
Manasa J; Varghese V; Pond SLK; Rhee SY; Tzou PL; Fessel WJ; Jang KS; White E; Rögnvaldsson T; Katzenstein DA; Shafer RW
Sci Rep; 2017 Sep; 7(1):11559. PubMed ID: 28912582
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.
Sutherland KA; Ghosn J; Gregson J; Mbisa JL; Chaix ML; Cohen Codar I; Delfraissy JF; Delaugerre C; Gupta RK
J Antimicrob Chemother; 2015 Jan; 70(1):243-8. PubMed ID: 25228587
[TBL] [Abstract][Full Text] [Related]
8.
Datir R; Kemp S; El Bouzidi K; Mlchocova P; Goldstein R; Breuer J; Towers GJ; Jolly C; Quiñones-Mateu ME; Dakum PS; Ndembi N; Gupta RK
mBio; 2020 Nov; 11(6):. PubMed ID: 33144375
[TBL] [Abstract][Full Text] [Related]
9. Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.
Sutherland KA; Parry CM; McCormick A; Kapaata A; Lyagoba F; Kaleebu P; Gilks CF; Goodall R; Spyer M; Kityo C; Pillay D; Gupta RK;
PLoS One; 2015; 10(9):e0137834. PubMed ID: 26382239
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
Ghosn J; Delaugerre C; Flandre P; Galimand J; Cohen-Codar I; Raffi F; Delfraissy JF; Rouzioux C; Chaix ML
PLoS One; 2011; 6(9):e24798. PubMed ID: 21949754
[TBL] [Abstract][Full Text] [Related]
11. Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy.
Tzou PL; Rhee SY; Pond SLK; Manasa J; Shafer RW
Sci Data; 2018 Jul; 5():180147. PubMed ID: 30040081
[TBL] [Abstract][Full Text] [Related]
12. Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1.
Sutherland KA; Mbisa JL; Cane PA; Pillay D; Parry CM
J Gen Virol; 2014 Jan; 95(Pt 1):190-200. PubMed ID: 24172906
[TBL] [Abstract][Full Text] [Related]
13. Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.
Thompson JA; Kityo C; Dunn D; Hoppe A; Ndashimye E; Hakim J; Kambugu A; van Oosterhout JJ; Arribas J; Mugyenyi P; Walker AS; Paton NI;
Clin Infect Dis; 2019 Mar; 68(7):1184-1192. PubMed ID: 30060027
[TBL] [Abstract][Full Text] [Related]
14. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
[TBL] [Abstract][Full Text] [Related]
15. Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?
Kletenkov K; Hoffmann D; Böni J; Yerly S; Aubert V; Schöni-Affolter F; Struck D; Verheyen J; Klimkait T;
J Antimicrob Chemother; 2017 Mar; 72(3):866-875. PubMed ID: 27999036
[TBL] [Abstract][Full Text] [Related]
16. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.
McKinnon JE; Delgado R; Pulido F; Shao W; Arribas JR; Mellors JW
Antivir Ther; 2011; 16(5):725-32. PubMed ID: 21817194
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genes.
Sutherland KA; Mbisa JL; Ghosn J; Chaix ML; Cohen-Codar I; Hue S; Delfraissy JF; Delaugerre C; Gupta RK
J Antimicrob Chemother; 2014 Dec; 69(12):3340-8. PubMed ID: 25096075
[TBL] [Abstract][Full Text] [Related]
18. Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.
Teto G; Nka AD; Fokam J; Bouba Y; Takou D; Fabeni L; Carioti L; Armenia D; Semengue ENJ; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Ndjolo A
Sci Rep; 2022 Jan; 12(1):1374. PubMed ID: 35082353
[TBL] [Abstract][Full Text] [Related]
19. Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs.
Su CT; Koh DW; Gan SK
Molecules; 2019 Sep; 24(18):. PubMed ID: 31489889
[TBL] [Abstract][Full Text] [Related]
20. Baseline PI susceptibility by HIV-1 Gag-protease phenotyping and subsequent virological suppression with PI-based second-line ART in Nigeria.
Datir R; El Bouzidi K; Dakum P; Ndembi N; Gupta RK
J Antimicrob Chemother; 2019 May; 74(5):1402-1407. PubMed ID: 30726945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
